Method of Treating Inflammatory Lung Disease
Pharmaceutical compositions comprising an isolated form of a compound of Formula I or IA (e.g., anatabine or S-(−)-anatabine) or a salt thereof can be used to treat disorders comprising an inflammatory component, including chronic, low-level inflammation. Compounds of Formula I also can be provided, for example, in other vehicles such as beverage products and consumer products such as lotions and creams.
1 . A method of treating an inflammatory lung disease, comprising administering to an individual in need thereof a composition comprising a therapeutically effective dose of an isolated form of a compound of Formula I
wherein:
R represents hydrogen or C 1 -C 5 alkyl;
R′ represents hydrogen or C 1 -C 7 alkyl;
X represents halogen or C 1 -C 7 alkyl;
“a” represents an integer from 0-4;
“b” represents an integer from 0-8; and
the dotted line within the piperidine ring represents (i) a carbon/carbon or carbon/nitrogen double bond and a carbon/carbon double bond conjugated thereto, or (ii) a carbon/nitrogen double bond;
or a pharmaceutically acceptable salt thereof; and
a pharmaceutically acceptable vehicle therefor.
2 . The method of claim 1 , wherein the compound of Formula I is anatabine or a pharmaceutically acceptable salt thereof.
3 . The method of claim 2 , wherein the salt is anatabine citrate.
4 . The method of claim 1 , wherein the compound of Formula I is S-(−)-anatabine or a pharmaceutically acceptable salt thereof.
5 . The method of claim 4 , wherein the salt is S-(−)-anatabine citrate.
6 . The method of claim 1 , wherein the inflammatory lung disease is chronic lung disease.
7 . The method of claim 1 , wherein the inflammatory lung disease is large-cell undifferentiated lung carcinoma.
8 . The method of claim 1 , wherein the inflammatory lung disease is lung adenocarcinoma.
9 . The method of claim 1 , wherein the inflammatory lung disease is small cell lung cancer.
10 . The method of claim 1 , wherein the inflammatory lung disease is squamous non-small cell lung cancer.
11 . The method of claim 1 , wherein the inflammatory lung disease is acute respiratory distress syndrome.
12 . The method of claim 1 , wherein the dose is in an immediate release formulation.
13 . The method of claim 1 , wherein the dose is in an extended release formulation.
14 . The method of claim 1 , wherein the dose is in a controlled release formulation.
15 . The method of claim 1 , wherein the dose is in a delayed release formulation.
16 . The method of claim 1 , wherein in the dose is administered by inhalation spray.
17 . The method of claim 1 , wherein the dose is administered nasally.
18 . The method of claim 1 , wherein the dose is from about 0.1 to about 1.5 mg/kg body weight.
19 . A method of treating chronic obstructive pulmonary disease, comprising administering to an individual in need thereof a composition comprising a therapeutically effective dose of anatabine or a pharmaceutically acceptable salt thereof.
20 . The method of claim 19 , wherein the salt is anatabine citrate.
21 . The method of claim 19 , wherein the anatabine is S-(−)-anatabine or a pharmaceutically acceptable salt thereof.
22 . The method of claim 21 , wherein the salt is S-(−)-anatabine citrate.
23 . The method of claim 19 , wherein the dose is from about 0.1 to about 1.5 mg/kg body weight.